Western European countries especially Germany, Italy and United Kingdom have led the market in Europe in terms of manufacturing & consumption of POCT devices. Application of POCT devices in diverse fields of defence, forensics and oncology has led the market in the region.
Mergers and acquisitions (M&A) has been a crucial competitive strategy for players to capture higher market share, access new technology and to expand product offerings in Europe. Data management of POCT has emerged as an upcoming revenue stream for these companies.
Blood Glucose POCT, Infectious POCT and Cardiac POCT would be the leading product segments in terms of sales by the end of the forecast period.
POCT market in Europe has been estimated to grow registering a CAGR of close to 6% in the forecast period. This growth would be supported by the launch of new products, entry of new players, innovative technological revolution and increase in reliability on POCT products by home patients & institutional buyers. Technology innovation in molecular diagnostics is a major driver within the infectious disease POCT for HAIs and STDs. HIV-1, HCV, c.difficle, Chlamydia, H. Pylori, Strep A/B, Influenza A/B, RSV, Ebola and Zika have widespread in Europe during the review period. Highly sensitive cardiac troponins that are the efficacy equivalent to centralized lab testing will increase the adoption of POC cardiac markers in POC settings. CK-MB, myoglobin, BNP, NT-proBNP and D-dimers are simultaneously being used in emergency settings. Inevitable pharamcoeconomic benefits in POC cardiac testing propels this segment to achieve its highest growth potential. Increase in reliability & trust in POCT devices by home users & hospitals, more incidence of diseases such as HIV, infectious, cardiac and others, increase in the number of hospitals, clinics, pathology labs in Europe, growth in nano technology and chip-on-phone miniaturization would provide major thrust to the market.